David F. Hale
D avid Hale is a co-founder and Director of Neurelis. He is Chairman and CEO of Hale BioPharma Ventures, LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic, and medical device companies. He currently serves as the Chairman of the Board of Oncternal Therapeutics, Inc., an oncology company, and as a director of Dermata, Inc., a dermatology company. He served as Chairman of Santarus, Inc., prior to its sale to Salix Pharmaceuticals, Inc. in 2014; SkinMedica, Inc., prior to its sale to Allergan in 2012; Micromet, Inc., prior to its sale to Amgen Inc. in 2012; Somaxon Pharmaceuticals prior to its sale to Pernix in 2013; and Crisi Medical Systems prior to its sale to Becton, Dickinson & Company in 2015.
Mr. Hale is a serial entrepreneur who has been involved in the formation and development of a number of biomedical companies.
In 1982, after joining Hybritech, Inc., the first monoclonal antibody company, Mr. Hale served as COO and President, and then Chief Executive Officer when Hybritech was acquired by Eli Lilly and Co. in 1986. From 1987 to 1997 he was Chairman, President, and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor, Inc., and was then acquired by Teva Pharmaceuticals. He co-founded and was Chairman of Viagene, Inc. from 1987 to 1995, when Viagene was acquired by Chiron, Inc. He co-founded LMA North America in 1997 and served as Chairman until its merger with LMA International in 2004. He was President and CEO of Women First HealthCare, Inc., from late 1997 to June 2000, prior to joining CancerVax in October 2000, where he served as President and CEO from 2000 until its merger with Micromet, Inc. in 2006, when he became Chairman.
Prior to joining Hybritech, Mr. Hale was Vice President and General Manager of BBL Microbiology Systems, a division of Becton, Dickinson & Company from 1971 to 1980, and held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc.